Patients Treated with ALL Therapy Inotuzumab Ozogamicin Report Better Quality of Life
May 25th 2018Patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) who were treated with inotuzumab ozogamicin (InO) indicated better quality of life, functioning, and symptom scores compared with patients receiving standard-of-care chemotherapies.
Read More
Study: Disparities Seen in Lung Cancer Care, Outcomes Between United States and England
May 24th 2018Researchers compared lung cancer care and outcomes, including patient characteristics, stage of cancer at diagnosis, treatment, and overall survival of patients in the United States and England.
Read More